Sarah M Markowitz1, Matthew M Carper, Jeffrey S Gonzalez, Linda M Delahanty, Steven A Safren. 1. Department of Psychology, Wells College, Aurora, New York (Dr Markowitz); Ferkauf Graduate School of Psychology and Albert Einstein College of Medicine, Yeshiva University, New York, NewYork (Dr Gonzalez); and Diabetes Research Center (Ms Delahanty) and Behavioral Medicine Service (Mr Carper and Dr Safren), Massachusetts General Hospital and Harvard Medical School, Boston.
Abstract
OBJECTIVE: Depression is one of the most common psychological problems affecting individuals with type 1 diabetes, and it is associated with treatment nonadherence and worse clinical outcomes. The research on treating depression or nonadherence in adults with type 1 diabetes is limited. We adapted an evidence-supported treatment, individual cognitive-behavioral therapy for adherence and depression (CBT-AD), for type 1 diabetes and examined its feasibility, acceptability, and potential for an effect. METHOD: The pilot study included 9 patients with a DSM-IV diagnosis of major depression, dysthymia, or residual depressive symptoms despite treatment with an antidepressant; a diagnosis of type 1 diabetes per patient self-report; and a glycosylated hemoglobin A1c (HbA1c) level of 8.0% or greater. Patients were referred by their diabetes care providers to a behavioral medicine specialty setting and received 10 to 12 sessions of CBT-AD. Main outcome measures included percent of eligible participants who enrolled in the study, session attendance, independently-rated Montgomery-Asberg Depression Rating Scale (MADRS) score, self-reported adherence to diabetes care activities, and adherence to self-monitoring of blood glucose levels. Data were collected from June 27, 2008, through March 31, 2010. RESULTS: There was a clinically meaningful decrease in depression severity (mean [SD] MADRS score decrease from 26.0 [4.73] to 12.3 [7.37], Cohen d = 2.90), demonstrated improvements in diabetes self-care (increase in blood glucose monitoring from 65.0 [26.72] to 82.7 [22.75], Cohen d = -0.66, and a difference in self-reported percent insulin doses in the past 2 weeks from 77.1 [29.84] to 87.1 [23.6], Cohen d = -0.34), and possible improvement in glycemic control (decrease in HbA1c levels from 9.6 [1.32] to 9.0 [1.04], Cohen d = 0.45). CONCLUSIONS: These preliminary results provide evidence for the acceptability, feasibility, and potential utility of CBT-AD for patients with type 1 diabetes and depression. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01527981.
OBJECTIVE:Depression is one of the most common psychological problems affecting individuals with type 1 diabetes, and it is associated with treatment nonadherence and worse clinical outcomes. The research on treating depression or nonadherence in adults with type 1 diabetes is limited. We adapted an evidence-supported treatment, individual cognitive-behavioral therapy for adherence and depression (CBT-AD), for type 1 diabetes and examined its feasibility, acceptability, and potential for an effect. METHOD: The pilot study included 9 patients with a DSM-IV diagnosis of major depression, dysthymia, or residual depressive symptoms despite treatment with an antidepressant; a diagnosis of type 1 diabetes per patient self-report; and a glycosylated hemoglobin A1c (HbA1c) level of 8.0% or greater. Patients were referred by their diabetes care providers to a behavioral medicine specialty setting and received 10 to 12 sessions of CBT-AD. Main outcome measures included percent of eligible participants who enrolled in the study, session attendance, independently-rated Montgomery-Asberg Depression Rating Scale (MADRS) score, self-reported adherence to diabetes care activities, and adherence to self-monitoring of blood glucose levels. Data were collected from June 27, 2008, through March 31, 2010. RESULTS: There was a clinically meaningful decrease in depression severity (mean [SD] MADRS score decrease from 26.0 [4.73] to 12.3 [7.37], Cohen d = 2.90), demonstrated improvements in diabetes self-care (increase in blood glucose monitoring from 65.0 [26.72] to 82.7 [22.75], Cohen d = -0.66, and a difference in self-reported percent insulin doses in the past 2 weeks from 77.1 [29.84] to 87.1 [23.6], Cohen d = -0.34), and possible improvement in glycemic control (decrease in HbA1c levels from 9.6 [1.32] to 9.0 [1.04], Cohen d = 0.45). CONCLUSIONS: These preliminary results provide evidence for the acceptability, feasibility, and potential utility of CBT-AD for patients with type 1 diabetes and depression. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01527981.
Authors: M A Van Tilburg; C C McCaskill; J D Lane; C L Edwards; A Bethel; M N Feinglos; R S Surwit Journal: Psychosom Med Date: 2001 Jul-Aug Impact factor: 4.312
Authors: Gregory E Simon; Wayne J Katon; Elizabeth H B Lin; Evette Ludman; Michael VonKorff; Paul Ciechanowski; Bessie A Young Journal: Gen Hosp Psychiatry Date: 2005 Sep-Oct Impact factor: 3.238
Authors: Evette J Ludman; Wayne Katon; Joan Russo; Michael Von Korff; Gregory Simon; Paul Ciechanowski; Elizabeth Lin; Terry Bush; Edward Walker; Bessie Young Journal: Gen Hosp Psychiatry Date: 2004 Nov-Dec Impact factor: 3.238
Authors: Steven A Safren; Conall O'Cleirigh; Judy Y Tan; Sudha R Raminani; Laura C Reilly; Michael W Otto; Kenneth H Mayer Journal: Health Psychol Date: 2009-01 Impact factor: 4.267
Authors: Jeffrey S Gonzalez; Lauren A McCarl; Deborah D Wexler D; Enrico Cagliero; Linda Delahanty; Tiffany D Soper; Valerie Goldman; Robert Knauz; Steven A Safren Journal: J Cogn Psychother Date: 2010-11-01
Authors: Steven A Safren; Jeffrey S Gonzalez; Deborah J Wexler; Christina Psaros; Linda M Delahanty; Aaron J Blashill; Aleksandra I Margolina; Enrico Cagliero Journal: Diabetes Care Date: 2013-10-29 Impact factor: 19.112